Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.

Competing Interests: Funding Support and Author Disclosures Dr Costanzo is a board member for Nuwellis; has received grant support from Abbott, Novartis, V-Wave, Bayer, and Alleviant; has received consulting income from Boehringer Ingelheim and Nuwellis; and participates in the data safety monitoring board for Merck. Dr Januzzi is a trustee of the American College of Cardiology; is a board member of Imbria Pharmaceuticals; is a director at Jana Care; has received grant support from Abbott, Applied Therapeutics, HeartFlow, Innolife, and Roche Diagnostics; has received consulting income from Abbott, Beckman, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck, Novartis, Pfizer, Roche Diagnostics, and Siemens; and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, CVRx, Intercept, and Takeda.